<DOC>
	<DOCNO>NCT01953861</DOCNO>
	<brief_summary>To evaluate effect food ( low high fat breakfast vs. fast ) pharmacokinetics ( body drug ) single dose solifenacin tamsulosin administer combination tablet EC905 . Also evaluate safety tolerability single dos EC905 young , healthy male subject , administer fed ( low high fat ) fasting condition .</brief_summary>
	<brief_title>A Study Evaluate Whether Food Has Effect Uptake Solifenacin Tamsulosin When Administered Combination Tablet</brief_title>
	<detailed_description>Subjects admit clinic Day -1 receive single dose combination tablet EC905 first day 3 period , three condition ( high fat breakfast , low fat breakfast , fast ) order evaluate effect food . Blood sample pharmacokinetic ( PK ) assessment perform dosing day 11 day dose period . This 11-day on-site period repeat three time subject dosed condition . Each period separate 7 day site . Subjects return End Study Visit ( ESV ) least 7 day last 11 day on-site period , withdrawal . On Day 1 3 period , subject give single dose EC905 three condition ( high fat breakfast , low fat breakfast fasting ) order evaluate effect food PK solifenacin tamsulosin HCl . The aim show absence food effect low fat breakfast vs. fast condition , evaluate food effect high fat breakfast vs. fast condition . Subjects randomize one 6 possible sequence fast fed condition . Screening take place Day -21 Day -1 . They admit clinic Day -1 . Blood sample PK assessment perform Day 1 Day 11 period . This 11 day on-site period repeat three time order allow subject dose fed ( low high fat ) fasting condition . The 11 day on-site period separate 7-day site period ; subject check eligibility one day prior start new dose day . Safety assessment perform throughout investigational period . Subjects return ESV least 7 day last 11 day on-site period , withdrawal .</detailed_description>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>BMI 18.5 30.0 kg/m2 , inclusive . Known suspected hypersensitivity solifenacin , tamsulosin recipient EC905 . Any contraindication precaution use mention applicable section Summary Product Characteristics ( SPC ) tamsulosin solifenacin Use grapefruit ( 3 x 200 ml ) marmalade ( three time ) week prior admission Clinical Unit , report subject .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Combination tablet EC905</keyword>
	<keyword>Omnic OCAS®</keyword>
	<keyword>Vesicare®</keyword>
	<keyword>Food effect</keyword>
	<keyword>Vesomni</keyword>
	<keyword>VesiFlow</keyword>
	<keyword>Urizia</keyword>
</DOC>